Drug-resistant TB is a serious public health issue in many developing countries, as its treatment is longer and requires more expensive drugs. MDR-TB is defined as resistance to the two most effective first-line TB drugs: rifampicin and isoniazid. "Extensively drug-resistant TB" is also resistant to three or more of the six classes of second-line drugs.